A study to learn about the amount of asundexian in the blood when healthy participants take different types of asundexian tablets
22665
Phase 1 other active
Quick answer
A study to learn about the amount of asundexian in the blood when healthy participants take different types of asundexian tablets for Prevention of ischemic stroke in patients post acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack is a Phase 1 program (other) at Bayer AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bayer AG
- Indication
- Prevention of ischemic stroke in patients post acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack
- Phase
- Phase 1
- Modality
- other
- Status
- active